Jason J. Luke
杰森·卢克
MD, FACP
Associate Professor of Medicine; Director, Cancer Immunotherapeutics Center医学副教授，癌症免疫治疗中心主任
👥Biography 个人简介
Jason J. Luke, MD, FACP is Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center, University of Pittsburgh. He is an internationally recognized expert in the development of novel immune-oncology combinations, particularly those targeting innate immune pathways including STING (stimulator of interferon genes) agonists, and in early-phase clinical trial design for melanoma and other solid tumors. Dr. Luke served as a principal investigator for the RELATIVITY-047 phase II/III trial, which established the combination of relatlimab (LAG-3 inhibitor) and nivolumab (PD-1 inhibitor) as superior to nivolumab monotherapy in treatment-naïve advanced melanoma—the first LAG-3 checkpoint inhibitor combination to achieve regulatory approval (FDA, 2022) and a landmark expansion of the co-inhibitory receptor blockade paradigm beyond PD-1 and CTLA-4. Dr. Luke leads an active translational program investigating the mechanistic basis of innate immune evasion and strategies to convert immunologically "cold" tumors to inflamed states amenable to checkpoint inhibition.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
RELATIVITY-047: Relatlimab + Nivolumab — First LAG-3 Approval
Served as a principal investigator for RELATIVITY-047, the phase II/III trial demonstrating that fixed-dose relatlimab plus nivolumab significantly improved median PFS (10.1 vs. 4.6 months) compared with nivolumab alone in treatment-naïve advanced melanoma, leading to FDA approval of this combination in 2022 as the first LAG-3-targeted immunotherapy and establishing dual checkpoint blockade beyond CTLA-4 as a viable paradigm.
STING Agonist Development in Solid Tumors
Pioneered early-phase clinical evaluation of STING agonists (including intratumoral and systemic formulations) as tools to activate innate immune sensing and overcome primary resistance to PD-1 blockade in melanoma and other solid tumors, leading trials of ADU-S100, MK-1454, and SR-717 in combination with checkpoint inhibitors.
Tumor Immune Microenvironment Profiling for Combination Strategy Design
Developed and applied multi-platform tumor microenvironment profiling (spatial transcriptomics, multiplexed immunohistochemistry, scRNA-seq) to characterize the immunological determinants of primary resistance to checkpoint inhibitor therapy in melanoma, providing mechanistic frameworks for rational innate immune combination design.
Novel Checkpoint and Co-stimulatory Pathway Clinical Development
Led or co-led early-phase trials of multiple novel checkpoint inhibitors and agonists including anti-TIM-3, anti-TIGIT, OX40 agonists, and IL-2 cytokine engineering approaches in melanoma and solid tumors, contributing to the identification of next-generation immune oncology targets beyond the established PD-1/CTLA-4/LAG-3 axis.
Representative Works 代表性著作
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma (RELATIVITY-047)
New England Journal of Medicine (2022)
Phase II/III RELATIVITY-047 trial demonstrating superior PFS with relatlimab + nivolumab versus nivolumab in first-line advanced melanoma, leading to the first FDA-approved LAG-3 checkpoint inhibitor combination.
Phase I/II Clinical Trial of a STING Agonist MK-1454 in Combination with Pembrolizumab
Journal for ImmunoTherapy of Cancer (2022)
First reported clinical results for intratumoral STING agonist MK-1454 combined with pembrolizumab demonstrating systemic abscopal-like responses in injected and non-injected melanoma and other solid tumors.
Tumor Microenvironment of Metastatic Melanoma Treated with Combination of Nivolumab and Ipilimumab
Cancer Cell (2022)
Spatial and single-cell multi-omic analysis of pre- and on-treatment tumor biopsies from combination immunotherapy-treated melanoma, identifying T-cell and myeloid state transitions associated with response versus resistance.
The Future of Checkpoint Therapy in Melanoma: Targeting LAG-3 and Beyond
Nature Reviews Clinical Oncology (2023)
Comprehensive review synthesizing the mechanistic biology of LAG-3, TIM-3, TIGIT, and VISTA co-inhibitory receptors and mapping the clinical trial landscape for next-generation checkpoint combination strategies in melanoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
关注 杰森·卢克 的研究动态
Follow Jason J. Luke's research updates
留下邮箱，当我们发布与 Jason J. Luke（UPMC Hillman Cancer Center / University of Pittsburgh）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment